Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,572,540
  • Shares Outstanding, K 71,949
  • Annual Sales, $ 47,070 K
  • Annual Income, $ -223,860 K
  • EBIT $ -332 M
  • EBITDA $ -339 M
  • 60-Month Beta 2.21
  • Price/Sales 167.62
  • Price/Cash Flow N/A
  • Price/Book 7.18

Options Overview Details

View History
  • Implied Volatility 59.84% (+1.67%)
  • Historical Volatility 42.77%
  • IV Percentile 19%
  • IV Rank 12.22%
  • IV High 153.30% on 12/05/25
  • IV Low 46.82% on 08/18/25
  • Expected Move (DTE 19) 10.07 (11.03%)
  • Put/Call Vol Ratio 0.90
  • Today's Volume 184
  • Volume Avg (30-Day) 152
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 2,335
  • Open Int (30-Day) 2,356
  • Expected Range 81.28 to 101.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.89
  • Number of Estimates 8
  • High Estimate -0.71
  • Low Estimate -0.98
  • Prior Year -0.82
  • Growth Rate Est. (year over year) -8.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.00 +30.50%
on 01/29/26
95.90 -4.74%
on 02/26/26
+19.20 (+26.61%)
since 01/27/26
3-Month
63.69 +43.43%
on 12/02/25
103.00 -11.31%
on 12/08/25
+23.49 (+34.62%)
since 11/26/25
52-Week
19.44 +369.91%
on 04/09/25
103.00 -11.31%
on 12/08/25
+61.10 (+201.98%)
since 02/27/25

Most Recent Stories

More News
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated...

KYMR : 91.35 (-3.87%)
Kymera Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 91.35 (-3.87%)
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 91.35 (-3.87%)
Kymera Therapeutics to Participate in Upcoming February Investor Conferences

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 91.35 (-3.87%)
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027...

KYMR : 91.35 (-3.87%)
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial...

KYMR : 91.35 (-3.87%)
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 91.35 (-3.87%)
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks

Institutional insiders are placing big bets on DASH, KVUE, and KYMR. See how much is being spent on these three stocks and which investors are buying.

KYMR : 91.35 (-3.87%)
KMB : 111.44 (+0.96%)
KVUE : 19.12 (+0.63%)
DASH : 176.47 (-2.18%)
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 91.35 (-3.87%)
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial  KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported...

KYMR : 91.35 (-3.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 99.15
2nd Resistance Point 96.57
1st Resistance Point 93.96
Last Price 91.35
1st Support Level 88.77
2nd Support Level 86.19
3rd Support Level 83.58

See More

52-Week High 103.00
Last Price 91.35
Fibonacci 61.8% 71.08
Fibonacci 50% 61.22
Fibonacci 38.2% 51.36
52-Week Low 19.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar